Compare Enveric Biosciences Inc (ENVB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Merck & Co., Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 52659.2× Enveric Biosciences Inc's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Merck & Co., Inc. for 98 Days on average.
| ENVB | MRK | |
|---|---|---|
Market Cap | $6.69M | $352.29B |
Volume | 41,141 | 6,348,796 |
Sector | Health | Health |
52-Week High | $10.80 | $156.43 |
52-Week Low | $1.27 | $82.49 |
Typical Hold Time | 14 Days | 98 Days |
Enterprise Value | -$1.60M | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
